Tekmira Pharmaceuticals Corporation Announces Completion of US$30 Million Public Offering of Common Stock

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has completed its previously announced underwritten public offering of 3,750,000 shares of its common stock, at a public offering price of $8.00 per share, representing gross proceeds of US$30.0 million. The underwriters have been granted a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering to cover over-allotments.

Help employers find you! Check out all the jobs and post your resume.

Back to news